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Status epilepticus is a life-threatening neurologic emergency. The elderly constitute the largest and
fastest continuously growing population among patients with status epilepticus. The complexity of
clinical presentations and difﬁculty in diagnosis further complicate, and possibly delay, prompt man-
agement. High clinical suspicion and proper investigation are the best tools for a prompt diagnosis. The
etiology of elder-onset status epilepticus is primarily symptomatic, and cerebrovascular diseases are one
of the most common causes, followed by neurodegenerative diseases such as dementia. Status epi-
lepticus causes signiﬁcant mortality among the elderly, who have the highest mortality of all age groups.
These patients are very different from other age groups in many respects and clinicians should never
treat them in the same manner as younger adults. Status epilepticus warrants immediate treatment to
prevent irreversible neuronal damage. Decision-making regarding the choice of antiepileptic drugs
(AEDs) depends on many factors such as adverse effect tolerability, drug interactions, and medical
comorbidities. Balancing efﬁcacy with the adverse effects of antiepileptic drugs is needed. The newer
intravenous antiepileptic drugs, which have fewer adverse effects and drug interactions, appear to be
reasonable treatment options for elderly patients. However, more evidence from clinical trials in this
speciﬁc age group is required.
Copyright © 2016, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Most generalized convulsive seizures stop quickly and sponta-
neously, whereas status epilepticus (SE) is a common neurological
emergency that causes high mortality and irreversible neuronal
damage if unsuccessfully treated. Status epilepticus is a seizure
lasting more than 30 minutes or intermittent seizures without the
recovery of consciousness between seizures1. However, based on
the short duration of typical seizures (1e2 minutes)2 and evidence
of neuronal injury resulting from prolonged seizure, it was pro-
posed that SE should be operationally deﬁned as a seizure lasting
more than 5minutes to hasten intervention and treatment3. Elderly
people (i.e., older than 65 years) have the highest prevalence and
incidence of SE, and the prevalence further increases with
advancing age. Because of the continuing aging of the worldwidere that they have no conﬂicts
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es/by-nc-nd/4.0/).population, ﬁrst-line clinicians are treating an increasing number of
elderly patients with SE. It is important to note that elderly patients
differ from younger adults in many respects. Management of
elderly patients with SE involves unique considerations regarding
epidemiology, etiology, prognosis, and treatment choice. Articles
included in this review were identiﬁed through searches of
PubMed from 1988 until August 1, 2015, using the terms “epilepsy”,
“status epilepticus,” “elderly,” and “aged.” Only papers published in
English were reviewed. The ﬁnal list of included articles was based
on the relevance to the topics in this review article.2. Epidemiology
One retrospective study4 that calculated the cumulative inci-
dence of SE reported that 0.4% of the general population will have
experienced at least one episode of SE by the age of 75 years. The
age-speciﬁc incidence rate of SE reﬂects a U-shaped curve or a
bimodal distributionwith peak rates among infants and the elderly.
The incidence of epilepsy and SE has signiﬁcantly declined in
children and young adults with a concurrent increase among the
elderly5. A landmark study conducted in Richmond, VA, USA
showed an annual incidence of SE in the elderly of 86 cases pericine. Published by Elsevier Taiwan LLC. This is an open access article under the CC
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general population6. The 70e79-year-old subgroup had an even
higher annual incidence of 100 cases per 100,000 individuals.
Similar results have been reported in other studies with different
inclusion criteria, which reveals the fast growth and continuing rise
in the annual incidence of SE in the older age group7.
3. Clinical features and classiﬁcation
Status epilepticus has a wide variety of clinical presentations
and electroencephalography (EEG) features. Similar to epilepsy,
several classiﬁcation schemes of SE have been proposed. Status
epilepticus can simply be divided into convulsive SE or non-
convulsive SE, based on the presence of clinically signiﬁcant motor
activity. Each group can be further divided by the consciousness
level and clinical/EEG features8. Patients are categorized as mark-
edly/severely impaired or as normal/mildly impaired, based on the
consciousness level. With regard to clinical semiology and ictal EEG
activity, patients are categorized into the generalized group or focal
group. Focal seizures with or without secondary generalization are
more common in elderly patients than in young adults. In the
Richmond study, 26% of elderly patients were categorized as having
generalized SE, whereas 29% of patients were categorized as having
focal seizures and 45% of patients were categorized as having focal
seizures with secondary generalization9. A caregiver or family
member may witness an elderly patient having a generalized
convulsive SE, although it is more likely a secondary generalized
seizure due to a previously unrecognized focal onset seizure10.
Unlike convulsive SE presenting with clinically obvious tonic,
clonic, or tonic-clonic movement of the extremities, nonconvulsive
status epilepticus (NCSE) is much more difﬁcult to recognize
because of the lack of signiﬁcantmotor phenomena. There is usually
only subtle twitching of the face or limbs, or nystagmoid eye
movement associated with a wide range of mental statuses from
mild confusion to coma. Nonconvulsive status epilepticus may arise
as the initial manifestation of seizure or result from the control of
convulsive SE11. Decades ago, NCSE in elderly patients was
described in the literature. It can be successfully treated after a
correct and prompt diagnosis12. The diagnostic challenge remains
because many conditions mimic NCSE such as metabolic encepha-
lopathy, delirium, psychosis, and drug intoxication. Patients may go
undiagnosed for days, even weeks, unless ﬁnally diagnosed by EEG
abnormalities. The exact prevalence or ratio of NCSE to all types of
SE is difﬁcult to determine, but it is more common in the elderly,
especially in settings of critical illness. Eight percent of all comatose
patients in intensive care units are diagnosed with NCSE, based on
EEG monitoring13. This percentage may reach as high as 37% if the
patient cohort is limited to individuals with otherwise unexplained
altered consciousness14. In a prospective study focused on elderly
patients with confusion of unknown origin, 16% of the patients were
diagnosed with NCSE by video-EEG; none of them had a history of
epilepsy15. Acute onset (i.e., within 24 hours) and lack of clinical
response to simple commands were associated with NCSE. In
another recent prospective study with continuous EEG monitoring
in elderly patients presenting with delirium, 28% of patients
showed EEG patterns that were compatible with NCSE but without
any other reliable clinical parameters for differential diagnosis16. A
high index of clinical suspicion and timely EEG conﬁrmation,
especially in elderly patients presenting with altered mental status,
are the best and probably the only ways to diagnose NCSE.
4. Etiology
Status epilepticus can occur in people with no previous history
of seizures or epilepsy, especially in elderly patients. More than 70%of elderly patients in the Richmond cohort developed SE as their
ﬁrst-ever seizure7. The underlying causes of SE in elderly patients
are also different from the causes in children and young adults. The
etiologies are age-dependent and largely determine the prognosis
and mortality rate. The underlying cause of late-onset SE is mostly
symptomatic epilepsy (recently redeﬁned as “structuralemetabolic
epilepsy”)17, as opposed to idiopathic epilepsy (recently redeﬁned
as “genetic epilepsy”) that is common in young people18. In the
Richmond study6, an acute cerebrovascular accident was reported
as the cause of SE in 21% of elderly patients. Remote symptomatic
causes, which were mostly cases of a prior stroke, contributed
another 21%. Other etiologies such as hypoxia, metabolic
derangement, low AED concentration, traumatic brain injury, and
central nervous system infection occur at any age, and still
contribute to a substantial number of cases, just as in other age
groups. When acute and remote strokes were combined, cerebro-
vascular events represented the most important etiology in elderly
SE, whereas stroke was relatively uncommon in young adults and
children. Similar ﬁndings were consistently noted in many studies
across different countries19. A retrospective study in Taiwan also
indicated cerebrovascular disease as the leading cause among pa-
tients who experienced their ﬁrst-ever SE after the age of
60 years20.
The relationship between stroke and SE is complex and not well
understood. Status epilepticus occurs in more than 25% of early
poststroke seizures21. Status epilepticus may present as the ﬁrst
symptom of stroke or at any time during the acute phase of the
stroke (i.e., within 14 days). Stroke patients with SE have higher
mortality and poorer functional disability, compared to stroke pa-
tients without SE22. Moreover, early-onset poststroke SE is associ-
ated with a high risk of recurrent seizure23. Outside the acute stage,
SE more commonly occurs in stroke survivors with a relatively
stable neurological condition. A large retrospective study of post-
stroke patients with a mean age of 72 years showed that cerebral
infarctionwithin 1 year raised the seizure risk by 23-fold, compared
to the risk in the general population24. Poststroke patients with
greater disability tended to develop SE later.
Frequently under-recognized degenerative diseases such as
dementia are also associated with a high risk of late-onset epilepsy.
Compared to their controls, age- and sex-adjusted patients with
dementia had a six-fold increased risk of unprovoked seizure25. A
caseecontrol study of hospitalized inpatients older than 70 years
revealed nonvascular dementia as an independent predictor of SE
at an adjusted odds ratio of 4.1626. Patients with Alzheimer's dis-
ease had an even higher odds of seizure and epilepsy than in-
dividuals with non-Alzheimer's dementia in a nationwide inpatient
study27. A causal relationship between dementia pathology and the
development of SE has been proposed but the underlying mecha-
nism remains unclear28.
5. Prognosis and mortality
After the ﬁrst episode of SE, the overall mortality is more than
20%9. The mortality rate remained consistently high across
different epidemiological studies using various methodologies and
inclusion criteria29. The underlying cause of SE is the most impor-
tant factor affecting its prognosis and mortality rate. Potentially
fatal etiologies usually lead to unfavorable neurological outcomes.
An inadequate AED level and alcohol misuse have a relatively good
prognosis and low mortality rate (i.e., < 10%), whereas hypoxic
brain injury is associated with a high mortality rate (i.e.,
60e100%)30. Because of the differential distribution of SE etiologies
among the elderly, the mortality rate is also different from other
age groups. Unlike the U-shape curve of the age-speciﬁc incidence
mentioned previously, the mortality rate of SE is low in children
L.-A. Chen, S.-B. Jou4and high in the elderly31. One study collected 32 years' worth of
data from the National Hospital Discharge Survey in the United
States, and revealed that in-hospital mortality increased sharply
after the age of 50 years and approached 20% by the age of
80 years32. A nationwide population-based cohort study in Taiwan
further addressed age-dependent sex differences in themortality of
SE. In-hospital mortality increased abruptly in women older than
45 years33. Mortality in men consistently increased and peaked at
over 70 years of age. The reasons for this sex effect on the mortality
of SE remain controversial.
Age is a signiﬁcant predictor of the mortality of SE34. Various
studies emphasized a strong correlation between old age and
mortality after an episode of SE in a short-term follow up and in a
long-term follow up, which included a Taiwanese study showing
that a 1-year increase in age was linked to an increase in poor
outcomes of 7.5%35. A retrospective study showed that old age and
marked consciousness impairment in patients with SE were pre-
dictive of death36.
The Status Epilepticus Severity Score (STESS) is a simple clinical
scoring system that predicts outcomes in adult patients with SE37.
The STESS score ranges from0 to 6, and scores greater than3 indicate
unfavorable outcomes. Old age (i.e., older than 65 years), which
scores2points, is themost important item in this scoring system.Old
age is a poor prognostic factor, probably because elderly patients
more commonly experience fatal etiologies of SE such as stroke,
systemicmetabolic derangement, or brain tumor. In addition, elderly
patients are vulnerable to complications of SE such as aspiration
pneumonia or physical injury during convulsions. They are also less
tolerant of the adverse effects of SE treatment such as AEDs, me-
chanical ventilation, or anesthetics used in refractory cases.
As mentioned earlier, the underlying cause was one of the most
important outcome predictors and stroke is a major etiology in the
elderly group. Status epilepticus after acute stroke had a signiﬁcant
impact on stroke mortality and on functional disability23.
Compared to acute stroke patients without seizure, patients with
SE of cerebrovascular origin had a signiﬁcantly higher long-term
fatality rate with a hazard ratio of 2.1238. In a prospective study,
acute stroke patients with SE exhibited a three-fold increase in
mortality, compared to an age-, sex-, and infarct size-matched
control group. Synergistic effects of prolonged seizure and brain
ischemic injury on mortality have been proposed39.
6. Treatment
Several published guidelines exist for the management of adult
status epilepticus40,41, but no protocol for elderly SE has been
established because of a paucity of evidence and clinical trials. In
this paper, we discuss special considerations in convulsive SE
management in the elderly, especially with regard to intravenous
AEDs. Details of oral AED choice in elderly patients were previously
reviewed in this journal42. The use of general anesthetic agents and
the principles of managing refractory or super-refractory SE is
beyond the scope of this article.
The prompt initiation of treatment for SE within 5e10 minutes
is crucial because of potential mortality and neuronal damage.Table 1
Proposed treatment algorithm for convulsive status epilepticus in the elderly9.
1. Initial treatment (i.e., for early status epilepticus). If seizures persist, lorazepam (0.1
be repeated once.
2. For established status epilepticus (i.e., 30~120 minutes), administer phenytoin [loadi
loading dose (e.g., 15 mg/kg) and intravenous infusion rate (e.g., up to 20 mg/min) is
dose of 15e30 mg/kg and intravenous infusion rate of 3e6 mg/kg/min) or levetirac
3. For refractory status epilepticus, midazolam (loading dose, 0.2 mg/kg; intravenous
infusion rate of 2e5 mg/kg/h). Beware of respiratory depression, sedation, and hypSeizure duration is a potentially manageable factor affecting mor-
tality43. Treatment goals are the rapid cessation of the clinical
seizure and EEG seizure without recurrence. Identiﬁcation of the
cause of seizure and the management of subsequent medical
complications also determine the outcomes of SE44.
The ﬁrst-line treatment in most protocols for SE is the imme-
diate administration of intravenous benzodiazepines. A large ran-
domized, double-blind study by the Veterans' Affairs Cooperative
Study Group45, which included many elderly patients with a mean
age of 59 years, showed the superiority of lorazepam over
phenytoin. Lorazepam is currently preferable to diazepam because
it has a longer duration of action, favorable pharmacokinetics, and a
lower risk of seizure recurrence46. A recent double-blinded com-
parison study between intravenous lorazepam and intramuscular
midazolam found that 20% of the patients were older than 60 years,
which indicated that midazolam was as effective as lorazepam at
terminating SE in a prehospital setting47. The ease of an adminis-
tration route, other than intravenous access, makes midazolam an
attractive alternative for the initial treatment of SE.
For patients who continue to have seizures after benzodiazepine
treatment, an intravenous AED should be administered for seizure
control. Intravenous phenytoin has beenwidely used but can cause
hypotension and arrhythmia when infused rapidly, especially in
elderly patients who already have a history of arrhythmias such as
atrioventricular block48. The recommended loading dose of intra-
venous phenytoin is 20 mg/kg in young adults, but it should be
decreased to 15 mg/kg in the elderly49. The maximal infusion rate
should also be decreased from 50 mg/min in younger adults to
20 mg/min in the elderly to prevent signiﬁcant changes in blood
pressure and heart rate. Close monitoring of vital signs during
phenytoin infusion is recommended, especially in elderly patients
with underlying cardiovascular comorbidities.
Valproic acid is another AED option if patients are unsuitable for
phenytoin treatment because of the concern of adverse cardiovas-
cular effects. Valproic acid is as effective as phenytoin in patients
unresponsive to ﬁrst-line benzodiazepines and is not associated
with cardiovascular or respiratory depression. It is safe and well
tolerated after rapid infusion, even in elderly patients with hypo-
tension50. A smaller loading dose may be sufﬁcient to achieve
adequate serum concentrations in elderly patients, but potential
drugedrug interactions still need to be considered51. Levetiracetam
is also a reasonable option for an intravenous AED because of its
favorable adverse effect proﬁle in the elderly and lack of drug
interaction (Table 1). Several small studies demonstrate the efﬁcacy
and safety of intravenous levetiracetam in the management of SE in
elderly patients52. An ongoing randomized trial is comparing intra-
venous fosphenytoin, valproic acid, and levetiracetam in a ran-
domized, blinded fashion and includes an elderly SE patient group53.
7. Conclusion and future directions
The incidence of SE in the elderly is increasing and is associated
with higher mortality, compared to other age groups worldwide.
The ictal phenomenon is usually recognized as having a focal onset
or as secondary generalized convulsive SE. However, themg/kg; intravenous, 2 mg/min) or midazolam (intramuscular, 10 mg) may
ng dose of 20 mg/kg and intravenous infusion rate of 50 mg/min; however, a lower
preferred if there is a risk of hypotension or arrhythmia] or valproic acid (loading
etam (20e30 mg/kg; intravenous drip in 15 minutes).
infusion rate of 0.2e0.6 mg/kg/h) or propofol (loading dose, 2 mg/kg; intravenous
otension.
Status Epilepticus in the Elderly 5nonconvulsive form varies widely in clinical presentation, which
makes recognizing it early difﬁcult. The distinctive presentations of
elderly patients with SE make prompt clinical diagnosis and timely
management more challenging. A method to detect SE accurately
and early is essential, especially in places where continuous video-
EEG monitors are unavailable. The underlying etiologies of SE
largely determine the prognosis and outcome. The most common
cause of SE in the elderly is cerebrovascular disease. Status epi-
lepticus after a stroke further worsens the neurological outcomes of
stroke. More studies are needed to establish the relationship be-
tween these two common neurological emergencies. Treatment
options in elderly patients with SE have not been well studied and
an optimal management protocol has not been elucidated. The ef-
ﬁcacy and safety of intravenous AEDs are important when treating
elderly patients with multiple comorbidities and co-medications.
An ongoing clinical trial will address the efﬁcacy of the second-
line AEDs. Further research and clinical trials are needed to un-
derstand and care better for this special group of patients with SE.References
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